Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

NCT00125190 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Insulin-Like Growth Factor-1 Deficiency
Growth Disorders

Interventions

DRUG: rhIGF-1 (mecasermin) for a period of 86 weeks

Sponsor

Ipsen